Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD000544.pub4PMID 27158764PMCID PMC7045447
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cited by this paper
• Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.

  2014cited by this paper
• Comparison of QD and TID Oral Mesalazine for Maintenance of Remission in Quiescent Ulcerative Colitis: A Double-blind, Double-dummy, Randomized Multicenter Study

  2013cited by this paper
• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.

  2013cited by this paper
• Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.

  2012cited by this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2012cited by this paper
• Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis

  2012cited by this paper
• One-year Investigator-blind Randomized Multicenter Trial Comparing Asacol 2.4 g Once Daily with 800 mg Three Times Daily for Maintenance of Remission in Ulcerative Colitis

  2011cited by this paper
• Chapter 12: Interpreting results and drawing conclusions

  2011cited by this paper
• Randomised clinical trial: a comparative dose‐finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

  2011cited by this paper
• Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial

  2010cited by this paper
• Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: A double-blind, randomized study

  2010cited by this paper
• Clinical trial: ulcerative colitis maintenance treatment with 5‐ASA: a 1‐year, randomized multicentre study comparing MMX® with Asacol®

  2009cited by this paper
• Effect of extended MMX mesalamine therapy for acute, mild‐to‐moderate Ulcerative Colitis

  2009cited by this paper
• MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.

  2009cited by this paper
• Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.

  2009cited by this paper
• Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial

  2008cited by this paper
• Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

  2008cited by this paper
• GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

  2008cited by this paper
• The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis

  2008cited by this paper
• Predictors of Medication Adherence in Inflammatory Bowel Disease

  2007cited by this paper
• Effect of weekend 5‐aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: Results from a randomized controlled study

  2007cited by this paper
• 5-ASA Prescription Refill Rates for Ulcerative Colitis Are Independent of Formulation and Dosing Regimens: 1144

  2006cited by this paper
• Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis

  2006cited by this paper
• Systematic review: adherence issues in the treatment of ulcerative colitis

  2006cited by this paper
• Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study

  2005cited by this paper
• Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis.

  2005cited by this paper
• A Prospective Randomized Observer-Blind 2-Year Trial of Azathioprine Monotherapy versus Azathioprine and Olsalazine for the Maintenance of Remission of Steroid-Dependent Ulcerative Colitis

  2004cited by this paper
• Patient‐led variable dosing with balsalazide as long‐term therapy for maintenance in ulcerative colitis: a 3‐year prospective observational study

  2004cited by this paper
• Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease

  2003cited by this paper
• The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitis

  2003cited by this paper
• A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis.

  2003cited by this paper
• Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.

  2003influential reference
• The pharmacokinetic profiles of oral 5ASA formulations used in the management of ulcerative colitis: a systematic review

  2002cited by this paper
• Evaluation of renal function following treatment with 5‐aminosalicylic acid derivatives in patients with ulcerative colitis

  2002cited by this paper
• Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis

  2002cited by this paper
• Comparable systemic absorption of 5-ASA and N-AC-5-ASA from U.S. asacol and colazal

  2002cited by this paper
• Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.

  2002cited by this paper
• Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

  2001cited by this paper
• Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

  2001cited by this paper
• Increasing patient adherence to gastroenterology treatment and prevention regimens

  1999cited by this paper
• Is maintenance therapy always necessary for patients with ulcerative colitis in remission?

  1999cited by this paper
• Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis

  1999cited by this paper
• The systemic load and efficient delivery of active 5‐aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine

  1999cited by this paper
• Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months

  1998cited by this paper
• Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.

  1997cited by this paper
• Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.

  1997cited by this paper
• 5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis.

  1997cited by this paper
• Alternatives to Sulfasalazine: A Meta‐analysis of 5‐ASA in the Treatment of Ulcerative Colitis

  1997cited by this paper
• Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

  1997cited by this paper
• A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.

  1997cited by this paper
• An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis

  1996cited by this paper
• Systemic availability of 5‐aminosalicylic acid: comparison of delayed release and an azo‐bond preparation

  1996cited by this paper
• Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine

  1996cited by this paper
• Systemic uptake of 5‐aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission: 526

  1996cited by this paper
• Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.

  1995cited by this paper
• Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

  1995cited by this paper
• Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.

  1995cited by this paper
• Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.

  1995cited by this paper
• Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.

  1995cited by this paper
• Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.

  1995cited by this paper
• Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

  1994cited by this paper
• Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis.

  1994cited by this paper
• Sulfasalazine Revisited

  1993cited by this paper
• Olsalazine in maintenance of clinical remission in patients with ulcerative colitis

  1993cited by this paper
• Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

  1993cited by this paper
• Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine

  1992cited by this paper
• Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.

  1992cited by this paper
• Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day

  1992cited by this paper
• Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.

  1992cited by this paper
• Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.

  1992cited by this paper
• Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months

  1992cited by this paper
• Pentasa in maintenance treatment of ulcerative colitis.

  1990cited by this paper
• Comparable efficacy of oral 5-aminosalicylic acid (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission.

  1990cited by this paper
• Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

  1990cited by this paper
• Comparative efficacy of coated, oral 5‐aminosalicylic acid (Claversal * ) and sulphasalazine for maintaining remission of ulcerative colitis

  1989cited by this paper
• Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis.

  1989cited by this paper
• Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.

  1988cited by this paper
• Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.

  1988cited by this paper
• Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis.

  1988cited by this paper
• Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double‐blind comparison with sulphasalazine

  1988cited by this paper
• Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.

  1988cited by this paper
• Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis.

  1988cited by this paper
• Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.

  1987cited by this paper
• Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution.

  1987cited by this paper
• Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel disease

  1987cited by this paper
• Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.

  1987cited by this paper
• Olsalazine in patients intolerant of sulphasalazine.

  1987cited by this paper
• Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties.

  1986cited by this paper
• Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

  1983cited by this paper
• Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide

  1983cited by this paper
• Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.

  1983cited by this paper
• Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.

  1982cited by this paper
• An oral preparation to release drugs in the human colon.

  1982cited by this paper
• Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease.

  1982cited by this paper
• Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.

  1982cited by this paper
• 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.

  1982cited by this paper
• Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

  1980cited by this paper

• Management of Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis Pre- and Post-liver Transplantation.

  2026cites this paper
• Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies

  2025cites this paper
• Management of diarrhoea in patients with stable ulcerative colitis with low FODMAP diet, amitriptyline, ondansetron or loperamide: the MODULATE RCT.

  2025cites this paper
• Clinical observation of probiotics combined with mesalazine and Yiyi Baitouweng Decoction retention enema in treating mild-to-moderate ulcerative colitis

  2025cites this paper
• Outcomes of 5-aminosalicylates withdrawal due to non-adherence in ulcerative colitis patients: A step toward evaluating intermittent therapy

  2025cites this paper
• Ten-Year Trend in 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients with Ulcerative Colitis: An Analysis of Korean Health Insurance Data.

  2025cites this paper
• Optimizing 5-Aminosalicylic Acid Maintenance Treatment in Ulcerative Colitis from the Patient and Physician Perspective: A Cross-sectional Multicenter Study

  2025cites this paper
• Effect of Intermittent Fasting on Immune Parameters and Intestinal Inflammation

  2024cites this paper
• Characteristics of Mucosa-Associated Microbiota in Ulcerative Colitis Patients with 5-Aminosalicylic Acid Intolerance

  2024cites this paper
• Practical management of mild-to-moderate ulcerative colitis: an international expert consensus

  2024cites this paper
• Common Mistakes in Managing Patients with Inflammatory Bowel Disease

  2024cites this paper
• Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023

  2024cites this paper
• The evolving understanding of histology as an endpoint in ulcerative colitis

  2024cites this paper
• New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases

  2024cites this paper
• Sinomenine hydrochloride improves DSS-induced colitis in mice through inhibition of the Notch signaling pathway

  2024cites this paper
• Bifidobacterium longum CECT 30763 improves depressive- and anxiety-like behavior in a social defeat mouse model through the immune and dopaminergic systems.

  2024cites this paper
• GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline.

  2023cites this paper
• Optimizing treatment of mild to moderate ulcerative colitis: CU-Forum Delphi Consensus.

  2023cites this paper
• Prevention of Colitis-Associated Cancer via Oral Administration of M13-Loaded Lipid Nanoparticles

  2023cites this paper
• Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics

  2023cites this paper
• Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction

  2023cites this paper
• The Impacts of Fecal Microbiota Transplantation from Same Sex on the Symptoms of Ulcerative Colitis Patients

  2023cites this paper
• Ulcerative Colitis in Adults: A Review.

  2023cites this paper
• Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis

  2022cites this paper
• Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis

  2022cites this paper
• Targeted colonic release formulations of mesalazine - A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis.

  2022cites this paper
• Oxymatrine attenuates TNBS-induced colinutis in rats through TLR9/Myd88/NF-κB signal pathway

  2022cites this paper
• Medication Adherence and Its Influencing Factors Among Inflammatory Bowel Disease Patients in China

  2022cites this paper
• An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis

  2022cites this paper
• Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia

  2022cites this paper
• Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy

  2022cites this paper
• Actualización de la guía de práctica clínica PANCCO para el tratamiento de la colitis ulcerativa en población adulta

  2022cites this paper
• Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis

  2021cites this paper
• Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis

  2021cites this paper
• Hybrid Nanocomposite Platform, Based on Carbon Nanotubes and Poly(Methylene Blue) Redox Polymer Synthesized in Ethaline Deep Eutectic Solvent for Electrochemical Determination of 5-Aminosalicylic Acid

  2021cites this paper
• Evidence-based clinical practice guidelines for inflammatory bowel disease 2020

  2021cites this paper
• Identification of the key characteristics of Bifidobacterium longum strains for the alleviation of ulcerative colitis.

  2021cites this paper
• Luteolin suppresses 5-hydroxytryptamine elevation in stimulated RBL-2H3 cells and experimental colitis mice

  2021cites this paper
• Bifidobacterium Longum: Protection against Inflammatory Bowel Disease

  2021cites this paper
• Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S‐methyltransferase inhibition

  2021cites this paper
• Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase

  2021cites this paper
• Recombinant CRAMP-producing Lactococcus lactis attenuates dextran sulfate sodium-induced colitis by colonic colonization and inhibiting p38/NF-κB signaling

  2021cites this paper
• 6-thioguanine nucleotide monitoring in azathioprine and mercaptopurine monotherapy for the treatment of inflammatory bowel disease

  2021cites this paper
• Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.

  2020cites this paper
• Probiotics for maintenance of remission in ulcerative colitis.

  2020cites this paper
• Exopolysaccharides from Bacillus amyloliquefaciens DMBA-K4 ameliorate dextran sodium sulfate-induced colitis via gut microbiota modulation

  2020cites this paper
• Escherichia coli‐associated granulomatous colitis in dogs treated according to antimicrobial susceptibility profiling

  2020cites this paper
• Pharmacogenetics of inflammatory bowel disease.

  2020cites this paper
• Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.

  2020cites this paper
• Inflammatory bowel disease and targeted oral anti-TNFα therapy.

  2020cites this paper
• 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis

  2020cites this paper
• c9, t11, c15-CLNA and c9, t11, t15-CLNA from Lactobacillus plantarum ZS2058 Ameliorate DSS-Induced Colitis in Mice.

  2020cites this paper
• Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.

  2020cites this paper
• Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes

  2020cites this paper
• Rumex japonicus Houtt. alleviates dextran sulfate sodium-induced colitis by protecting tight junctions in mice

  2020cites this paper
• Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease

  2020cites this paper
• Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases

  2020cites this paper
• Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission

  2020cites this paper
• Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia

  2020cites this paper
• Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study

  2020cites this paper
• IBD considerations in spondyloarthritis

  2020cites this paper
• Treat to target in mild to moderate ulcerative colitis: evidence to support this strategy.

  2020cites this paper
• Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis

  2020cites this paper
• GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach.

  2020cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2020cites this paper
• Gut Microbiome Changes in Patients with Active Left-Sided Ulcerative Colitis after Fecal Microbiome Transplantation and Topical 5-aminosalicylic Acid Therapy

  2020cites this paper
• A Web-Based Decision Aid (myAID) to Enhance Quality of Life, Empowerment, Decision Making, and Disease Control for Patients With Ulcerative Colitis: Protocol for a Cluster Randomized Controlled Trial

  2019cites this paper
• Systematic review with meta‐analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies

  2019cites this paper
• Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study

  2019cites this paper
• Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review.

  2019cites this paper
• A ropy exopolysaccharide producing strain Bifidobacterium longum subsp. longum YS108R alleviates DSS-induced colitis by maintenance of the mucosal barrier and gut microbiota modulation.

  2019cites this paper
• Role of Fecal Microbiota Transplantation for Maintenance of Remission in Patients with Ulcerative Colitis: A Pilot Study.

  2019cites this paper
• Mucosal 5‐aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis

  2019cites this paper
• Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system

  2019cites this paper
• Remission induction, maintenance, and endoscopic outcome with oral 5‐aminosalicylic acid in intestinal Behçet's disease

  2019cites this paper
• Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?

  2019cites this paper
• Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance

  2019cites this paper
• Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics

  2019cites this paper
• No increased risk of nephrotoxicity associated with 5‐aminosalicylic acid in IBD: a population‐based cohort and nested case‐control study

  2019cites this paper
• Pinocembrin Protects Against Dextran Sulfate Sodium-Induced Rats Colitis by Ameliorating Inflammation, Improving Barrier Function and Modulating Gut Microbiota

  2019cites this paper
• Innovations in Oral Therapies for Inflammatory Bowel Disease

  2019cites this paper
• The culprit of mesalamine intolerance: case series and literature review

  2019cites this paper
• Thymol has beneficial effects on the experimental model of ulcerative colitis

  2019cites this paper
• Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States

  2019cites this paper
• British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

  2019cites this paper
• Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents

  2019cites this paper
• Recent advances in understanding and managing pediatric inflammatory bowel disease

  2019cites this paper
• Contemporary Management of Ulcerative Colitis

  2018cites this paper
• Nonbiological therapeutic management of ulcerative colitis

  2018cites this paper
• European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease

  2018cites this paper
• The Detergent Effect of Mesalazine Interferes with Phosphatidylcholine Binding to Mucin 2

  2018cites this paper
• Patient Preference and Physician Perceptions of Patient Preference for Oral Pharmaceutical Formulations: Results from a Real-Life Survey

  2018cites this paper
• Anti-inflammatory effect of fucoxanthin on dextran sulfate sodium-induced colitis in mice

  2018cites this paper
• Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

  2018cites this paper
• Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.

  2018cites this paper
• Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East

  2018cites this paper
• Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.

  2018cites this paper
• Role of soybean-derived bioactive compounds in inflammatory bowel disease

  2018cites this paper
• A Probiotic for Ulcerative Colitis: The Culture Wars Continue

  2018cites this paper
• Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease

  2018cites this paper